U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07753993) titled 'A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.' on Aug. 04.
Brief Summary: This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled multicenter study to investigate outcomes with elecoglipron compared with placebo in participants with CKD with and without T2DM who are on background SGLT2i (dapagliflozin) as GDMT and other SoC treatments for CKD.
Study Start Date: Aug. 28
Study Type: INTERVENTIONAL
Condition:
Chronic Kidney Disease
Intervention:
DRUG: Elecoglipron
Elicoglipron tablet
DRUG: Placebo
Placebo tablet
Recruitment ...